Real-World Study of More than 700,000 People with Type 2 Diabetes (T2D) Shows No Increased Risk of Below-Knee Lower Extremity Amputations with INVOKANA ® (canagliflozin) Compared to Other Diabetes Medications

Source: Johnson and Johnson - Category: Pharmaceuticals Source Type: news